Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CSTL Stock Forecast 2025-2026
$19.46
Current Price
$583.51M
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CSTL Price Targets
+110.7%
To High Target of $41.00
+85.0%
To Median Target of $36.00
+54.2%
To Low Target of $30.00
CSTL Price Momentum
-4.3%
1 Week Change
+10.6%
1 Month Change
+8.4%
1 Year Change
-27.0%
Year-to-Date Change
-45.7%
From 52W High of $35.84
+26.0%
From 52W Low of $15.45
📊 TOP ANALYST CALLS
Did CSTL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Castle Biosciences is one of their latest high-conviction picks.
Latest CSTL Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, CSTL has a bullish consensus with a median price target of $36.00 (ranging from $30.00 to $41.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $19.46, the median forecast implies a 85.0% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mason Carrico at Stephens & Co., projecting a 110.7% upside. Conversely, the most conservative target is provided by Mark Massaro at BTIG, suggesting a 54.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CSTL Analyst Ratings
9
Buy
0
Hold
0
Sell
CSTL Price Target Range
Low
$30.00
Average
$36.00
High
$41.00
Current: $19.46
Latest CSTL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CSTL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 21, 2025 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $40.00 |
| May 6, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $37.00 |
| May 6, 2025 | Lake Street | Thomas Flaten | Buy | Maintains | $35.00 |
| Feb 28, 2025 | Baird | Catherine Ramsey | Outperform | Maintains | $37.00 |
| Jan 2, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $41.00 |
| Nov 6, 2024 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $44.00 |
| Nov 5, 2024 | Lake Street | Thomas Flaten | Buy | Maintains | $40.00 |
| Nov 5, 2024 | Keybanc | Paul Knight | Overweight | Maintains | $36.00 |
| Nov 5, 2024 | Baird | Catherine Ramsey | Outperform | Maintains | $39.00 |
| Oct 29, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $42.00 |
| Oct 14, 2024 | BTIG | Sung Ji Nam | Buy | Maintains | $40.00 |
| Aug 6, 2024 | Baird | Catherine Ramsey | Outperform | Maintains | $37.00 |
| Aug 6, 2024 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $37.00 |
| Jul 5, 2024 | Baird | Catherine Ramsey | Outperform | Maintains | $34.00 |
| May 3, 2024 | Baird | Catherine Ramsey | Outperform | Maintains | $34.00 |
| Mar 1, 2024 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $37.00 |
| Mar 1, 2024 | Keybanc | Paul Knight | Overweight | Maintains | $28.00 |
| Dec 14, 2023 | Guggenheim | Subbu Nambi | Buy | Initiates | $25.00 |
| Aug 4, 2023 | Keybanc | Paul Knight | Overweight | Maintains | $25.00 |
| Jul 7, 2023 | Lake Street | Thomas Flaten | Buy | Reiterates | $32.00 |
Castle Biosciences Inc. (CSTL) Competitors
The following stocks are similar to Castle Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CSTL
Castle Biosciences
mkt cap
586.11M
Castle Biosciences Inc. (CSTL) Financial Data
Castle Biosciences Inc. has a market capitalization of $583.51M with a P/E ratio of 30.5x. The company generates $347.08M in trailing twelve-month revenue with a -1.5% profit margin.
Revenue growth is +20.6% quarter-over-quarter, while maintaining an operating margin of -31.7% and return on equity of -1.2%.
Valuation Metrics
Market Cap
$583.51M
Enterprise Value
$340.27M
P/E Ratio
30.5x
PEG Ratio
-10.0x
Price/Sales
1.7x
Growth & Margins
Revenue Growth (YoY)
+20.6%
Gross Margin
+81.4%
Operating Margin
-31.7%
Net Margin
-1.5%
EPS Growth
+20.6%
Financial Health
Cash/Price Ratio
+49.0%
Current Ratio
9.4x
Debt/Equity
5.9x
ROE
-1.2%
ROA
-1.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Castle Biosciences Inc. (CSTL) Business Model
About Castle Biosciences Inc.
What They Do
Develops diagnostic tests for dermatological cancers.
Business Model
Castle Biosciences generates revenue by developing and commercializing proprietary diagnostic tests, such as DecisionDx-Melanoma and DecisionDx-SCC, which help healthcare providers make informed treatment decisions for patients with skin cancers. By offering actionable insights, the company enhances the ability of clinicians to tailor treatments to individual patient needs, thereby improving patient outcomes.
Additional Information
The company operates at the intersection of diagnostics and personalized medicine, significantly impacting the fields of biotechnology and healthcare. Its focus on precision medicine and innovative tools aims to improve survivorship outcomes in patients with complex oncology cases.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
784
CEO
Mr. Derek J. Maetzold
Country
United States
IPO Year
N/A
Website
castlebiosciences.comCastle Biosciences Inc. (CSTL) Latest News & Analysis
Latest News
Quick Summary
Castle Biosciences granted 135,978 restricted stock units to 66 employees on June 14, 2025, as part of its 2022 Inducement Plan, per Nasdaq rule 5635(c)(4).
Why It Matters
The granting of RSUs to new employees signals confidence in the company's growth and aims to attract talent, potentially boosting future performance and shareholder value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) has partnered with SciBase Holding AB to develop a diagnostic test for predicting flares in atopic dermatitis using Electrical Impedance Spectroscopy technology.
Why It Matters
Castle Biosciences' collaboration with SciBase enhances its diagnostic capabilities, potentially driving revenue growth and market share in dermatology, crucial for investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Castle Biosciences CEO Derek Maetzold will join a panel at the BIO 2025 convention to discuss challenges in commercializing diagnostic tests and strategies for precision medicine.
Why It Matters
Castle Biosciences' CEO's participation in a key industry panel highlights the company's leadership in precision medicine, potentially boosting investor confidence and impacting share performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Castle Biosciences CEO Derek Maetzold received a Lifetime Achievement Award from the American Business Awards for his leadership in healthcare, particularly in molecular diagnostics and precision medicine.
Why It Matters
Recognition of Castle Biosciences' leadership may boost investor confidence, signaling strong management and potential for continued innovation and growth in the healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Castle Biosciences (Nasdaq: CSTL) will present new research on melanoma at the ASCO Annual Meeting, showcasing findings from a study involving over 13,500 patients using DecisionDx-Melanoma.
Why It Matters
Castle Biosciences' presentation at ASCO highlights its innovative melanoma tests and collaboration with the NCI, potentially boosting investor confidence in its growth and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Castle's executive team will present a company overview at the Jefferies Global Healthcare Conference on June 4, 2025, at 7:35 am ET.
Why It Matters
Castle's presentation at a major healthcare conference could influence investor sentiment, provide insights into its strategy, and highlight growth opportunities or challenges ahead.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CSTL Stock
What is Castle Biosciences Inc.'s (CSTL) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Castle Biosciences Inc. (CSTL) has a median price target of $36.00. The highest price target is $41.00 and the lowest is $30.00.
Is CSTL stock a good investment in 2026?
According to current analyst ratings, CSTL has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $19.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CSTL stock?
Wall Street analysts predict CSTL stock could reach $36.00 in the next 12 months. This represents a 85.0% increase from the current price of $19.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Castle Biosciences Inc.'s business model?
Castle Biosciences generates revenue by developing and commercializing proprietary diagnostic tests, such as DecisionDx-Melanoma and DecisionDx-SCC, which help healthcare providers make informed treatment decisions for patients with skin cancers. By offering actionable insights, the company enhances the ability of clinicians to tailor treatments to individual patient needs, thereby improving patient outcomes.
What is the highest forecasted price for CSTL Castle Biosciences Inc.?
The highest price target for CSTL is $41.00 from Mason Carrico at Stephens & Co., which represents a 110.7% increase from the current price of $19.46.
What is the lowest forecasted price for CSTL Castle Biosciences Inc.?
The lowest price target for CSTL is $30.00 from Mark Massaro at BTIG, which represents a 54.2% increase from the current price of $19.46.
What is the overall CSTL consensus from analysts for Castle Biosciences Inc.?
The overall analyst consensus for CSTL is bullish. Out of 11 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $36.00.
How accurate are CSTL stock price projections?
Stock price projections, including those for Castle Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 8, 2025 4:49 AM UTC